Millennium Management
AVTX icon

Millennium Management’s Avalo Therapeutics AVTX Stock Holding History

Millennium Management’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12.5M Buy
835,484
+175,505
+27% +$2.74M 0.01% 1960
2025
Q4 		$12M Buy
659,979
+522,548
+380% +$8.82M 0.01% 2073
2025
Q3 		$1.75M Buy
+137,431
New +$1.18M ﹤0.01% 4186
2023
Q3 		– Sell
-141
Closed -$12.1K – 6107
2023
Q2 		$12.1K Sell
141
-119
-46% -$80.1K ﹤0.01% 5732
2023
Q1 		$109K Buy
260
+80
+44% +$63K ﹤0.01% 5394
2022
Q4 		$220K Sell
180
-33
-15% -$43K ﹤0.01% 5279
2022
Q3 		$169K Sell
213
-138
-39% -$150K ﹤0.01% 5751
2022
Q2 		$506K Buy
+351
New +$470K ﹤0.01% 4942
2021
Q4 		– Sell
-65
Closed -$411K – 6772
2021
Q3 		$411K Sell
65
-1
-2% -$8.11K ﹤0.01% 5521
2021
Q2 		$621K Buy
66
+61
+1,220% +$511K ﹤0.01% 5108
2021
Q1 		$43K Buy
+5
New +$47.2K ﹤0.01% 5784
2020
Q4 		– Sell
-6
Closed -$39 – 5185
2020
Q3 		$39 Sell
6
-49
-89% -$368K ﹤0.01% 4314
2020
Q2 		$413K Buy
55
+31
+129% +$225K ﹤0.01% 3517
2020
Q1 		$168K Buy
+24
New +$254K ﹤0.01% 3441
2019
Q4 		– Sell
-32
Closed -$305K – 4193
2019
Q3 		$305K Buy
+32
New +$357K ﹤0.01% 3557
2019
Q2 		– Sell
-51
Closed -$861K – 4040
2019
Q1 		$861K Buy
51
+46
+920% +$688K ﹤0.01% 2953
2018
Q4 		$44K Sell
5
-17
-77% -$189K ﹤0.01% 3624
2018
Q3 		$292K Buy
+22
New +$288K ﹤0.01% 3494
2016
Q3 		– Sell
-5
Closed -$29K – 3259
2016
Q2 		$29K Sell
5
-9
-64% -$81.8K ﹤0.01% 3093
2016
Q1 		$150K Buy
+14
New +$138K ﹤0.01% 3016

Other funds holding AVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Millennium Management's AVTX Position: Q1 2026 in Review

Millennium Management increased its Avalo Therapeutics (AVTX) stake by 27% in Q1 2026, buying an estimated $2.74M and bringing the position to 835,484 shares worth $12.5M. The position accounts for 0.01% of the portfolio, ranked #1960.

Millennium Management first reported a position in AVTX in Q1 2016 and has held it in 20 quarters since. 97 funds tracked by Wall St. Rank hold AVTX as of Q1 2026.

  • Millennium Management held 835,484 shares of Avalo Therapeutics worth $12.5M as of Q1 2026.
  • Millennium Management bought 175,505 Avalo Therapeutics shares in Q1 2026, an estimated $2.74M.
  • Avalo Therapeutics made up 0.01% of Millennium Management's portfolio in Q1 2026, its #1960 holding.
  • Millennium Management first reported a position in Avalo Therapeutics in Q1 2016 and has held it in 20 quarters since.
  • 97 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.